- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.08. | Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial | ||
| 25.08. | New Jazz cancer drug approval could drive blockbuster sales | ||
| 25.08. | Roche, Eli Lilly get FDA nod for new Alzheimer's blood test | ||
| 25.08. | Will a 'reset' reignite investment in women's health startups? | ||
| 25.08. | Young startups miss out on biotech venture funding rebound, MassBio says | ||
| 24.08. | Safety concerns spur FDA to again halt testing of Regenxbio gene therapy | ||
| 24.08. | Roche commits to lean-mass preservation with Hanmi obesity deal | ||
| 24.08. | FDA extends review of Capricor cell therapy; Pain drug startup to go public | ||
| 24.08. | Cellares, a cell therapy manufacturing specialist, to lay off 100 employees | ||
| 24.08. | [Podcast] (Season 2) The Progress Profile: Alzheimer's Research in Focus | ||
| 24.08. | Pharma marketers need a share-of-answer strategy before AI spend | ||
| 21.08. | Shareholder pressures Capricor; Lilly dives deeper into vaccines | ||
| 21.08. | How cost and perception could reshape the GLP-1 market | ||
| 20.08. | Regeneron to challenge Ipsen as FDA clears bone disease drug | ||
| 20.08. | Cancer vaccine win restores Wall Street's faith in Moderna | ||
| 20.08. | Ultragenyx, after setbacks, nabs first gene therapy approval | ||
| 19.08. | Trump reportedly plans to tap policy aide Overton to lead FDA | ||
| 19.08. | Moderna and Merck cancer vaccine returns 'landmark' result in melanoma | ||
| 18.08. | BioMarin acquires experimental drug for rare bone disorder in $275M deal | ||
| 18.08. | Leo Pharma buys rare skin disease drug in $435M deal | ||
| 18.08. | AstraZeneca's win in lung cancer; Sandoz inks a China deal | ||
| 18.08. | Amylyx's bet on a GLP-1 blocker pays off | ||
| 17.08. | Argenx jumps on Phase 3 data for blockbuster Vyvgart | ||
| 17.08. | AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer | ||
| 17.08. | Slate Medicines, Fulcrum Therapeutics to combine in reverse merger |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.